PFE - Atea downgraded at JPMorgan on shrinking COVID opportunity
2023-08-10 10:20:13 ET
More on Atea
- Atea Pharmaceuticals, Inc. 2023 Q2 - Results - Earnings Call Presentation
- Atea Pharmaceuticals, Inc. ( AVIR ) Q2 2023 Earnings Call Transcript
- Atea rejects takeover offer from Tang Capital Partners
- Atea Pharmaceuticals jumps on $5.75 a share takeover offer from Tang Capital
- Atea wins FDA Fast Track status for dengue treatment
For further details see:
Atea downgraded at JPMorgan on shrinking COVID opportunity